Our Services
The first visit includes a 60 minutes psychiatric evaluation with Dr. Salehinia, during which he will review medical and psychiatric history.
Where needed, he may recommend lab work, such as blood tests. Once the assessment is complete, he will recommend a 30 minutes follow up visit to go over your diagnosis and discuss a comprehensive treatment plan.
Please note that typically medication is not prescribed during the first consultation, as treatment usually starts after the assessment has been completed.
Medication will be carefully prescribed, only where a need for medication is identified following an assessment.
Dr. Salehinia offers convenient, secure and HIPAA-compliant telepsychiatry in three state of Maryland, Virginia and California and if he determines that this is a good fit for you.
Follow-up appointments are recommended depending on Dr. Salehinia’s recommended treatment plan and last 30 minutes.
These are generally arranged to take place on a monthly basis, however the frequency of follow-up depends on the treatment plan and can therefore be more frequent.
For example, if there is a change in medication a follow-up appointment may be required within a week of the the first assessment.
Dr. Salehinia’s experience ranges from mental health to psychiatric and complex neuropsychiatric conditions, and he has been consulting psychiatrists, neurologists, internist and other specialties in different settings such as hospitals, outpatient, residential centers, stated facilities for years.
Dr. Salehinia provides thorough, professionally prepared support letters and medical documentation for the appropriate authorities, insurance companies and the legal system, grounded in rigorous clinical assessment and a clear understanding of each patient's diagnosis and functional needs.
We approach every documentation request with the same care and precision we bring to all aspects of patient care, ensuring that our patients are accurately and effectively represented in the settings that matter most to them.
Spravato (esketamine) Nasal Spray: FDA approved for Treatment Resistant Depression and Depression with Suicidality.
Leqembi (lecanemab-irmb) evaluation and referral: Leqembi is breakthrough FDA-approved monoclonal antibody treatment for early Alzheimer’s disease, including mild cognitive impairment (MCI) or mild dementia.
Alpha-Stimulator: FDA-cleared device to treat anxiety, insomnia, and pain.
Conners Continuous Performance Test (Conners CPT 3): Evaluation with highly sensitive and specific computerized test design for evaluation and management of attention deficit.
